MX2020007081A - Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad. - Google Patents
Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad.Info
- Publication number
- MX2020007081A MX2020007081A MX2020007081A MX2020007081A MX2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- peptides
- cells
- materials
- diabetes
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 5
- 230000005784 autoimmunity Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 101150013553 CD40 gene Proteins 0.000 abstract 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 6
- 239000000463 material Substances 0.000 abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 abstract 2
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000001363 autoimmune Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000028709 inflammatory response Effects 0.000 abstract 2
- 230000002452 interceptive effect Effects 0.000 abstract 2
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614262P | 2018-01-05 | 2018-01-05 | |
| US16/184,129 US20190194290A1 (en) | 2010-10-19 | 2018-11-08 | Methods for preventing, modulating and/or reducing cardiovascular disease |
| PCT/US2019/012425 WO2019136307A1 (en) | 2018-01-05 | 2019-01-04 | Therapeutic peptides and methods for treating autoimmune related disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007081A true MX2020007081A (es) | 2020-10-28 |
Family
ID=67144298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007081A MX2020007081A (es) | 2018-01-05 | 2019-01-04 | Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3735260B1 (enExample) |
| JP (2) | JP7511242B2 (enExample) |
| CN (2) | CN111801110B (enExample) |
| AU (1) | AU2019205328B2 (enExample) |
| BR (1) | BR112020013716A2 (enExample) |
| CA (1) | CA3086193A1 (enExample) |
| MX (1) | MX2020007081A (enExample) |
| SG (1) | SG11202006494VA (enExample) |
| WO (1) | WO2019136307A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012054584A2 (en) | 2010-10-19 | 2012-04-26 | The Regents Of The University Of Colorado, A Body Corporate | Peptides for modulating t-cell activity and uses thereof |
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| US11744875B2 (en) | 2019-07-12 | 2023-09-05 | Op-T Llc | Peptides and methods for treating disease |
| US12048734B2 (en) | 2020-04-17 | 2024-07-30 | Op-T Llc | Bioactive peptides and methods of use thereof |
| WO2021231898A2 (en) * | 2020-05-14 | 2021-11-18 | Op-T Llc | Nanoparticle compositions and uses thereof |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| CN117471100B (zh) * | 2022-07-22 | 2026-05-01 | 暨南大学 | Th40细胞亚群在制备辅助诊断和评估系统性红斑狼疮疾病活动试剂盒中的应用 |
| CN115807071B (zh) * | 2022-09-02 | 2025-09-26 | 宁夏医科大学 | 检测试剂在制备2型糖尿病伴动脉粥样硬化诊断工具中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| CA2542984A1 (en) * | 2003-07-07 | 2005-01-27 | David H. Wagner | Methods for predicting development of auto-immune diseases and treatment of same |
| US7449200B2 (en) * | 2006-04-17 | 2008-11-11 | Gp Medical, Inc. | Nanoparticles for protein/peptide delivery and delivery means |
| WO2012054584A2 (en) * | 2010-10-19 | 2012-04-26 | The Regents Of The University Of Colorado, A Body Corporate | Peptides for modulating t-cell activity and uses thereof |
| CN104619722B (zh) * | 2012-06-22 | 2022-10-04 | 达特茅斯大学理事会 | 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途 |
| WO2015148389A2 (en) * | 2014-03-23 | 2015-10-01 | The Regents Of The University Of Colorado | Diagnosis of multiple sclerosis in human and animal subjects |
-
2019
- 2019-01-04 EP EP19736089.4A patent/EP3735260B1/en active Active
- 2019-01-04 BR BR112020013716-2A patent/BR112020013716A2/pt unknown
- 2019-01-04 CA CA3086193A patent/CA3086193A1/en active Pending
- 2019-01-04 CN CN201980017176.9A patent/CN111801110B/zh active Active
- 2019-01-04 AU AU2019205328A patent/AU2019205328B2/en active Active
- 2019-01-04 MX MX2020007081A patent/MX2020007081A/es unknown
- 2019-01-04 JP JP2020557124A patent/JP7511242B2/ja active Active
- 2019-01-04 WO PCT/US2019/012425 patent/WO2019136307A1/en not_active Ceased
- 2019-01-04 SG SG11202006494VA patent/SG11202006494VA/en unknown
- 2019-01-04 CN CN202411324616.4A patent/CN119157997A/zh active Pending
-
2024
- 2024-06-17 JP JP2024097199A patent/JP2024123100A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019136307A1 (en) | 2019-07-11 |
| JP2021510174A (ja) | 2021-04-15 |
| EP3735260B1 (en) | 2026-03-04 |
| AU2019205328A1 (en) | 2020-08-06 |
| CN111801110A (zh) | 2020-10-20 |
| CA3086193A1 (en) | 2019-07-11 |
| EP3735260A1 (en) | 2020-11-11 |
| CN111801110B (zh) | 2024-10-18 |
| SG11202006494VA (en) | 2020-08-28 |
| JP7511242B2 (ja) | 2024-07-05 |
| JP2024123100A (ja) | 2024-09-10 |
| EP3735260A4 (en) | 2021-12-08 |
| CN119157997A (zh) | 2024-12-20 |
| AU2019205328B2 (en) | 2025-04-03 |
| BR112020013716A2 (pt) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201291233A1 (ru) | Аналоги глюкагона | |
| TN2012000560A1 (en) | Glucagon analogues | |
| EA201590294A1 (ru) | Аналоги глюкагона | |
| PE20181338A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden | |
| Mousa et al. | Advances in pharmacotherapy for primary biliary cirrhosis | |
| NZ754961A (en) | Growth differentiation factor 15 (gdf-15) constructs | |
| BR112016008540A2 (pt) | análogos de glucagon | |
| WO2017181452A8 (zh) | Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化 | |
| AR080027A1 (es) | Proteinas de union a cd127 | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| CR20200229A (es) | Variantes e isoformas de anticuerpos con actividad biológica reducida | |
| MX2011006315A (es) | Analogos de glucagon. | |
| BR112014018210A2 (pt) | moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada | |
| MY188182A (en) | Acylated glucagon analogues | |
| CY1121332T1 (el) | Μiμhtiκα καλσιτονινης προς θεραπεια ασθενειων και διαταραχων | |
| EA201690494A1 (ru) | Ацилированные аналоги глюкагона | |
| TN2011000295A1 (en) | Glucagon analogues | |
| MX2011006314A (es) | Analogos de glucagon. | |
| Coelho et al. | HSP60: issues and insights on its therapeutic use as an immunoregulatory agent | |
| EP3421487A3 (en) | Peptides for modulating t-cell activity and uses thereof | |
| CL2020003292A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| Salles et al. | Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure | |
| PE20191529A1 (es) | Peptidos y metodos para el tratamiento de diabetes | |
| EP3849580A4 (en) | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THEIR USE IN THE TREATMENT OF FIBROSIS | |
| EP4375297A3 (en) | Antibodies to human complement factor c2b and methods of use |